Brief: Onxeo Says New Data Confirms Relevance Of Combining AsiDNA™ With PARPi In HRP Tumor Models

Valerio Therapeutics SA

09/03/2022 06:23

March 9 (Reuters) - Onxeo SA  ALONX.PA :
    * ONXEO'S NEW PRECLINICAL DATA CONFIRM RELEVANCE OF
COMBINING
ASIDNA™ WITH PARP INHIBITORS IN TREATING HOMOLOGOUS
RECOMBINATION PROFICIENT TUMORS

Source text for Eikon:  urn:newsml:reuters.com:*:nBw3Yf9Zda
Further company coverage:  ALONX.PA 

   

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 772 09 20;))